Sutro Biopharma STRO shares are trading higher on Monday after peer company Immunomedics, who also works to treat cancer, was acquired by Gilead.
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Its focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Sutro Biopharma shares were trading up 8.19% at $11.03 on Monday during the time of publication. The stock has a 52-week high of $13.91 and a 52-week low of $6.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.